Eszopiclone Tablet Stability via Particle Size Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Eszopiclone exhibits decreased chemical stability when compressed into tablets, particularly due to alkaline pH and high water content, leading to increased impurities and potential efficacy and safety issues, which existing formulations struggle to manage effectively.
Innovation Solution
A stable pharmaceutical composition of eszopiclone with particles larger than 100 µm, preferably between 200 µm and 500 µm, is developed, allowing for improved chemical stability even at higher pH levels and increased water content, using specific excipients and manufacturing processes to maintain impurity levels within permitted limits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If eszopiclone is compressed into tablets with conventional particle sizes, then the tablet can be manufactured with standard excipients, but the chemical stability of eszopiclone decreases and impurities increase
Solution Approach 1:
The patent applies parameter changes by modifying the particle size parameter of eszopiclone from conventional fine particles to particles with d(0.9) greater than 100 μm. This physical parameter change fundamentally alters the drug's interaction with excipients and water, thereby improving chemical stability and reducing impurity formation during tablet storage without requiring changes to the chemical structure or composition of the tablet formulation.
2Adaptability or versatility
If excipients with pH above 7 are used in eszopiclone tablets, then manufacturing flexibility increases, but eszopiclone degradation increases due to alkaline conditions
Solution Approach 1:
The invention utilizes parameter changes in particle size to alter the chemical environment interactions of eszopiclone. The larger particle size creates a physical barrier that reduces the impact of alkaline pH excipients on the drug substance, thereby enabling the use of excipients with pH above 7 without significant degradation. This resolves the contradiction by decoupling pH sensitivity from excipient selection through physical modification.
3Stability of the object's composition
If water content in the tablet is increased, then the tablet formulation becomes more stable against other degradation pathways, but eszopiclone degradation accelerates due to hydrolysis
Solution Approach 1:
The patent applies parameter changes by increasing the particle size of eszopiclone to d(0.9) > 100 μm, which reduces the surface area-to-volume ratio. This physical parameter change decreases the drug's exposure to water molecules, thereby reducing hydrolysis rate. Consequently, the formulation can tolerate higher water content from excipients or environmental moisture without significant hydrolytic degradation, resolving the contradiction between water content and chemical stability.
4Productivity
If fine particle eszopiclone is used, then dissolution and absorption are improved, but chemical stability decreases and more expensive drying processes are required
Solution Approach 1:
The invention applies parameter changes by optimizing the particle size parameter to d(0.9) > 100 μm, which represents a balance between dissolution performance and chemical stability. This particle size is sufficiently large to improve chemical stability by reducing surface area exposure to degrading agents, yet sufficiently small to maintain adequate dissolution and absorption characteristics. This resolves the contradiction by finding an optimal parameter value that satisfies both opposing requirements.
Data Source
AI summary
The present invention relates to a stable pharmaceutical composition of eszopiclone with a defined particle size.